Alnylam Advances RNAi Therapeutics for Neurological Diseases with Key Trial Updates
Event summary
- Alnylam initiated a Phase 2 study (APPlauDS) for mivelsiran in Down syndrome-associated Alzheimer’s disease, recruiting across 30 global sites.
- Phase 1 data for mivelsiran showed robust reductions in CSF sAPPβ (-89.9%) and Aβ42 (-70.2%) with no serious adverse events related to the drug.
- Alnylam completed enrollment in the Phase 2 cAPPricorn-1 study for mivelsiran in Cerebral Amyloid Angiopathy (CAA), with initial results expected in 2028.
- ALN-5288, an RNAi therapeutic targeting Microtubule-Associated Protein Tau (MAPT), began its first-in-human Phase 1 trial in late 2025.
The big picture
Alnylam is positioning itself as a leader in RNAi therapeutics for neurological diseases, leveraging its platform to target amyloid and tau proteins central to Alzheimer’s progression. The company’s progress with mivelsiran and ALN-5288 underscores the potential of gene-silencing technologies to address unmet needs in neurodegenerative disorders. With seven clinical programs in neuroscience indications, Alnylam is expanding its footprint in a high-stakes therapeutic area where transformative treatments remain scarce.
What we're watching
- Clinical Efficacy
- Whether mivelsiran can demonstrate disease-modifying potential in Down syndrome-associated Alzheimer’s and CAA.
- Regulatory Pathway
- The pace at which Alnylam advances its neuroscience pipeline through Phase 2 and Phase 3 trials.
- Competitive Positioning
- How Alnylam’s RNAi approach differentiates itself in the crowded Alzheimer’s disease treatment landscape.